Rakesh Sharma, MD
Psychiatry · Miami, FLNPI 1275032922
Payments from drug & device makers
What this record shows
Novartis accounts for 86.7% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2023 at $1,090 and has fallen 96.3% since, to $40 in 2025.
Across 12 payments — averaging $116.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1K
- Cvrx, Inc.$145
- Bayer$40
Across 6 payments — averaging $10,989 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$62K
- Abbott$4K
What the payments were for
- Travel & lodging$72052%
- Food & beverage$67348%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 9 | $1,207 |
| Cvrx, Inc. | 1 | $145 |
| Bayer | 2 | $40 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LEQVIO$1,031
- Barostim Neo System$145
How this compares
$1,393 in reported general payments places this provider in the 65th percentile of 2,059 psychiatry providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Aripiprazole | 12 | $1,229 |
| Clonazepam | 79 | $827 |
| Duloxetine Hcl | 14 | $729 |
| Bupropion XlBupropion Hcl | 22 | $714 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 31 | $656 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 14 | $450 |
| Mirtazapine | 26 | $360 |
| Lamotrigine | 11 | $275 |
| Sertraline Hcl | 33 | $185 |
| Escitalopram Oxalate | 30 | $160 |
| Quetiapine Fumarate | 11 | $159 |
| Zolpidem Tartrate | 15 | $158 |
| Alprazolam | 47 | $121 |
| Temazepam | 12 | $101 |
| Trazodone Hcl | 28 | $98 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Miami
- Kenny PerezMiami$453K
- Erik CabreraMiami$357K
- Miguel FloresMiami$176K
- Pedro RodriguezMiami$96K
- John NewcomerMiami$96K
- Patricia JunqueraMiami$80K
- Marc AgroninMiami$66K
- Andrew CutlerLakewood Ranch$5.7M
- Richard JacksonBoca Raton$3.6M
- Ilan MelnickCoral Gables$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.